Cellectar Biosciences announces executive leadership changes

Cellectar Biosciences named Chad Kolean as chief financial officer and promoted Jarrod Longcor to the role of chief operating officer. Kolean, a 30-year industry veteran, will replace Dov Elefant, who is leaving to pursue other opportunities.

The Florham Park-based company is focused on the discovery and development of drugs for the treatment of cancer.

Kolean returns to Cellectar after having served as chief financial officer to both Vivex Biologics, a regenerative medicine company, and Titan Spine, a spinal implant med-tech company sold to Medtronic.

“It is with great enthusiasm that I congratulate Jarrod for his promotion to chief operating officer and warmly welcome Chad back to the Cellectar family,” said James Caruso, CEO of Cellectar. “Chad is returning to us after further strengthening and broadening his impressive business acumen, having served as CFO to two commercial companies, one of which was sold for an attractive premium. We are very pleased to have him join us once again, with his deep understanding of the company and broad industry knowledge. We appreciate Dov’s contributions and wish him well.”

Prior roles Kolean also served in included as chief financial officer and treasurer for Pioneer Surgical Technology, a biologic and orthopedic implant company, through its merger with RTI Surgical. Early in his career, he held leadership positions of increasing responsibility at multinational companies and those within the health care space including Tomotherapy, Metavante Corp., Snap On, Herman Miller, Kaydon Corp. and Arthur Andersen.

Longcor will add the new role of COO to his chief business officer responsibilities. His added responsibilities will include overseeing the company’s growth as it continues to enhance its capabilities across the organization. Longcor will lead and provide strategic oversight of the company’s key functional areas to ensure operational excellence as Cellectar progresses through its clinical development programs and advances towards commercialization. Longcor has been with the company for six years as both a consultant and chief business officer.